Even when diabetic patients have normal to low levels of plasma renin activity, RAS inhibitors are still effective in reducing albuminuria; thus, supporting the role of the RAS in these compartments in the progression of diabetic nephropathy. This evidence concerns the gene REN and diabetic kidney disease.